Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL817040 | 0.93 | ALDH1A1 (0.33) | — | |
| SCHEMBL2386422 | 0.91 | ALDH1A1 (0.32) | — | |
| SCHEMBL2386417 | 0.91 | ALDH1A1 (0.32) | — | |
| SCHEMBL28488936 | 0.91 | ALDH1A1 (0.32) | — | |
| SCHEMBL29040729 | 0.86 | P2RX7 (0.32) | P2RX7 | |
| SCHEMBL5264454 | 0.82 | — | — | |
| SCHEMBL10979425 | 0.80 | — | — | |
| SCHEMBL3456698 | 0.79 | — | — | |
| SCHEMBL14269373 | 0.79 | PREP (0.31) | — | |
| SCHEMBL7258256 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200388876-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH SILICON CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-12-10 | — | — | US | claimed |
| US-7183354-B2 | Room temperature curable functionalized HNBR coating | LORD CORPORATION (US) | 2007-02-27 | — | — | US | claimed |
| JP-3086840-A | — | — | None | — | — | JP | disclosed |
| EP-4658644-A1 | 2-(PYRIDAZIN-3-YL)-5-(TRIFLUOROMETHYL)PHENOLS AS NLRP3 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-114716381-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114605327-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114573510-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12220401-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| CN-114591242-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-114341228-B | Cyclic polymer hydride, process for producing the same, and resin composition | 日本瑞翁株式会社 | 2024-11-26 | — | — | CN | disclosed |
| WO-1999017878-A1 | USE OF TRIS (TRIFLUORO METHYLSULFONYL) METHANE, IN ADDITION TO ALKALINE METAL SALTS AND ALKALINE-EARTH METAL SALTS THEREOF AS CATALYSTS DURING C-C BONDING SYNTHESES AND THE NOVEL Mg SALT OF TRIS (TRIFLUORO METHYLSULFONYL) METHANE | MERCK PATENT GMBH (DE) | 1999-04-15 | — | — | WO | disclosed |
| WO-1998026028-A1 | FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY | ORR WILLIAM C (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5338736-A | Treating congestive heart failure, hypertension | AMERICAN CYANAMID COMPANY (US) | 1994-08-16 | — | — | US | disclosed |
| JP-H0386840-A | PRODUCTION OF ALPHA,BETA-UNSATURATED CARBONYL COMPOUND | NIPPON ZEON CO LTD | 1991-04-11 | — | — | JP | disclosed |
| EP-0194077-A1 | Improvements in or relating to pheromones | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-09-10 | — | — | EP | disclosed |
| WO-1986004897-A1 | IMPROVEMENTS IN OR RELATING TO PHEROMONES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-08-28 | — | — | WO | disclosed |
| US-4495330-A | SILANE SCAVENGER IN ONE PACKAGE MOISTURE CURABLE COMPOSITION | GENERAL ELECTRIC COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| US-4430497-A | PRESENCE OF LEWIS ACID | GRUENENTHAL GMBH (DE) | 1984-02-07 | — | — | US | disclosed |
| EP-0059307-A1 | Preparation of 2-oxa-bicyclo(3.3.0)octane compounds and their derivatives | Grünenthal GmbH (DE) | 1982-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220401-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | P2RX7 2246/4885 |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | P2RX7 2246/4885 |
| US-20200388876-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH SILICON CONTAINING ELECTROLYTE ADDITIVES | SELENOI, SIK1, SIK2 | P2RX7 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.